Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Saizeng Medical Licenses TSHR Antibody to Yarrow for $1.4B in Graves’ Disease Deal

Fineline Cube Dec 16, 2025
Company Deals

uBriGene Partners with Circurna on circRNA Manufacturing for Global Trials

Fineline Cube Dec 16, 2025
Company Deals

Dren Bio, Sanofi Forge $1.8B B‑Cell Therapy Deal with US Co‑Promote Option

Fineline Cube Dec 16, 2025
Company Deals

Adaptive Licenses TCR Data to Pfizer in $890M Deal for Rheumatoid Arthritis

Fineline Cube Dec 16, 2025
Company Deals

Sobi Acquires Arthrosi for $1.5 Billion to Add Gout Drug to Portfolio

Fineline Cube Dec 15, 2025
Policy / Regulatory

FDA Removes Key RWE Limitation, Allowing Drug and Device Submissions Without Individual Patient Data

Fineline Cube Dec 16, 2025
Company Drug

Orelabrutinib First BTK Inhibitor to Hit Phase 3 in Lupus as InnoCare NMPA Filing Cleared

Fineline Cube Dec 16, 2025
Company Drug

ENHERTU Wins FDA Approval as First-Line HER2 Breast Cancer Therapy

Fineline Cube Dec 16, 2025
Company Deals

Cook Medical & Siemens Healthineers Partner to Launch First Radiation‑Free iMRI Suite

Fineline Cube Sep 17, 2025

Cook Medical and Siemens Healthineers (ETR: SHL) today announced a strategic collaboration aimed at redefining...

Company

Eli Lilly Unveils $5 B Virginia Facility to Scale Bioconjugate & Antibody Production

Fineline Cube Sep 17, 2025

Eli Lilly (NYSE: LLY) announced plans to construct a $5 billion manufacturing complex just west of...

Company

AstraZeneca China Decentralises Medical Affairs, Signals Shift in Global Strategy

Fineline Cube Sep 17, 2025

AstraZeneca (AZ; NASDAQ: AZN) China announced a sweeping re‑organisation that removes the country‑level Head of...

Company Drug

Ascletis Pharma Reports 28‑Day ASC30 Study Results at EASD

Fineline Cube Sep 17, 2025

Ascletis Pharma Inc. (HKG: 1672) announced that its Phase Ib multiple‑ascending‑dose (MAD) study of the oral...

Company Deals

Hisun Pharma Secures China Rights to Ascentawits’ First‑In‑Class Drug AST‑3424

Fineline Cube Sep 17, 2025

Zhejiang Hisun Pharmaceutical Co., Ltd. (SHA: 600267) announced today that it has signed an exclusive...

Policy / Regulatory

Guangdong Launches 5‑Year Plan to Streamline Import of Urgently Needed Drugs and Medical Devices

Fineline Cube Sep 17, 2025

The Guangdong Provincial Drug Administration and the Guangdong Provincial Health Commission jointly announced the “Administrative...

Company

GSK to Invest $30 B in the United States Over Five Years, Building Advanced Biopharma Facilities

Fineline Cube Sep 17, 2025

GlaxoSmithKline (GSK; NYSE: GSK) announced today a $30 billion U.S. investment program that will fund research...

Company Drug

Novo Nordisk to File US Approval for High‑Dose Wegovy, Aiming to Match Lilly’s Zepbound

Fineline Cube Sep 17, 2025

Novo Nordisk A/S (NYSE: NVO) has announced plans to seek U.S. regulatory approval for a...

Company Deals

Suzhou‑Based InnoBM Partners with Qilu Pharmaceutical on BM601 Metallic Embolic Microsphere

Fineline Cube Sep 17, 2025

InnoBM Pharmaceuticals Co., Ltd. and Qilu Pharmaceutical Co. have inked a collaboration agreement to commercialize...

Company Deals Drug

Shanghai Henlius Biotech Negotiates Potential Sale of HLX43 ADC to Johnson & Johnson and Roche

Fineline Cube Sep 17, 2025

Henlius Biotech Inc. (HKG: 2696) is reportedly in talks with global pharmaceutical giants Johnson & Johnson (J&J,...

Company Deals

Shenzhen Mindray Eyes $1 B+ Hong Kong IPO With Huatai, JPMorgan On Board

Fineline Cube Sep 17, 2025

Shenzhen Mindray Bio‑Medical Electronics Co. has confirmed that Huatai Securities and JPMorgan Chase & Co. are the...

Company Deals

Duoning Bio Secures Global License for Upstream Bio’s Biochemical Analyzer Portfolio

Fineline Cube Sep 17, 2025

Duoning Biotechnology Co., Ltd. announced a strategic partnership with Upstream Bio Inc., granting Duoning an...

Drug

CSPC’s ALMB-0166 Approved for Phase II Trials in Parkinson’s Disease

Fineline Cube Sep 17, 2025

CSPC Pharmaceutical Group Limited (HKG: 1093), a China-based company, announced on September 15, 2025, that...

Company Drug

Nanjing Leads Biolabs Doses First Patient in Opamtistomig Melanoma Trial

Fineline Cube Sep 17, 2025

Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced today that the first patient has been...

Company Drug

AstraZeneca Launches Ultomiris in China for gMG and NMOSD Treatments

Fineline Cube Sep 17, 2025

UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has announced the launch of Ultomiris (ravulizumab), a...

Company

AstraZeneca Pauses GBP 200m Cambridge R&D Investment Amid UK Funding Cuts

Fineline Cube Sep 17, 2025

On September 12, 2025, AstraZeneca (AZ; NASDAQ: AZN) confirmed it has paused its GBP 200m...

Company Drug

Novo Nordisk Rybelsus Gains Cardio Benefit from SOUL Trial

Fineline Cube Sep 16, 2025

Novo Nordisk A/S (NYSE: NVO) announced that the European Medicines Agency (EMA)’s Committee for Medicinal Products...

Drug

Guangzhou Baiyunshan Pharmaceutical Launches Phase I/II Trial for RET‑Targeted BYS10

Fineline Cube Sep 16, 2025

Guangzhou Baiyunshan Pharmaceutical Co., Ltd. (SHA: 600332) announced that the Center for Drug Evaluation (CDE)...

Company Drug

Sino Biopharmaceutical Secures NMPA Approval for Degarelix Generic in China

Fineline Cube Sep 16, 2025

Sino Biopharmaceutical Limited (HKG: 1177) announced that its subsidiary Jiangsu Chia Tai Tianqing Pharmaceutical Co.,...

Company Drug

Haisco Pharma Secures NMPA Approval for Anrikefon in Hemodialysis‑Related Pruritus

Fineline Cube Sep 16, 2025

Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that the China National Medical Products Administration...

Posts pagination

1 … 34 35 36 … 598

Recent updates

  • Orelabrutinib First BTK Inhibitor to Hit Phase 3 in Lupus as InnoCare NMPA Filing Cleared
  • Saizeng Medical Licenses TSHR Antibody to Yarrow for $1.4B in Graves’ Disease Deal
  • Zhicheng’s TAVR Robotic System Enters NMPA Innovation Pathway
  • ENHERTU Wins FDA Approval as First-Line HER2 Breast Cancer Therapy
  • FDA Removes Key RWE Limitation, Allowing Drug and Device Submissions Without Individual Patient Data
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Orelabrutinib First BTK Inhibitor to Hit Phase 3 in Lupus as InnoCare NMPA Filing Cleared

Company Deals

Saizeng Medical Licenses TSHR Antibody to Yarrow for $1.4B in Graves’ Disease Deal

Company Medical Device

Zhicheng’s TAVR Robotic System Enters NMPA Innovation Pathway

Company Drug

ENHERTU Wins FDA Approval as First-Line HER2 Breast Cancer Therapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.